Study Not Yet Enrolling
Lymphomas are cancers that arise from white blood cells in lymph nodes and often accumulate in organs such as blood, bone marrow, spleen and liver.
Lymphoma is the most common form of blood cancer and the third most common childhood cancer. There are more than 80 different subtypes of lymphoma, each with different treatment protocols and different outcomes. However, one in four patients do not know their subtype. It is important to know and understand the characteristics of your lymphoma subtype to get the best care.
Variants of lymphoma include non-Hodgkin lymphomas (NHL) – including diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), Burkitt/Burkitt-like lymphoma (BL/BLL), marginal zone lymphoma (MZL) – as well as Hodgkin lymphoma (HL), which will be included in this trial.
Clinical Trial Description:
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of eFT226. The study will evaluate weekly intravenous (IV) administration of eFT226.